Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. — DOLAF  

a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status Clinical Trial

Official title: An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib

Status Active, not recruiting

Clinical Trial Summary

This study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations or alterations of genes involved in homologous recombination repair (HRR) or microsatellite instability (MSI) status.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
• Breast Neoplasms
• ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

• NCT number: NCT04053322
• Study type: Interventional
• Source: UNICANCER
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 26, 2019
• Completion date: August 2027